Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. [PDF]
, 2014 BackgroundBevacizumab and temsirolimus are active agents in gynecologic tumors. Temsirolimus attenuates upregulation of HIF-1α levels, a resistance mechanism for antiangiogenics, and targets the PI3-kinase/AKT/mTOR axis, commonly aberrant in these tumors.
Falchook, Gerald S +9 more
core +7 more sources
Afatinib use in recurrent epithelial ovarian carcinoma. [PDF]
, 2019 •Genomic tumor testing is an important tool in guiding treatment for gynecologic malignancies.•Targetable mutations may lead to new therapies in gynecologic cancer treatment.•Her2/neu mutations in serous ovarian carcinomas can be targeted with ERBB2 ...
Alvarez, Edwin A +3 more
core +1 more source
Perioperative Laboratory Abnormalities in Gynecologic Oncology Surgical Patients [PDF]
, 2015 Background: Laboratory blood testing incurs financial costs and the blood draws can increase discomfort, yet minimal data exists regarding routine testing in gynecologic oncology surgical patients.
Burnett, Tatnai L. +6 more
core +1 more source
Robotic Surgery in Gynecologic Oncology [PDF]
Obstetrics and Gynecology International, 2011 Robotic surgery for the management of gynecologic cancers allows for minimally invasive surgical removal of cancer-bearing organs and tissues using sophisticated surgeon-manipulated, robotic surgical instrumentation. Early on, gynecologic oncologists recognized that minimally invasive surgery was associated with less surgical morbidity and that it ...
Robert Debernardo +4 more
openaire +4 more sources
Impact of chemotherapy-induced nausea and vomiting on quality of life in indonesian patients with gynecologic cancer. [PDF]
, 2011 Patients reported a negative impact on the QoL of delayed emesis after chemotherapy. Poor prophylaxis of patients' nausea and vomiting after chemotherapy interferes with patients' QoL.
Atthobari, Jarir +9 more
core +1 more source
Infection on a gynecologic oncology service [PDF]
Gynecologic Oncology, 1990 Little information is available pertaining to infectious morbidity in women with genital malignancy. To define the magnitude of this problem, all patients admitted to the gynecologic oncology services at the University of Michigan Medical Center between January 1, 1986, and December 31, 1986, were followed prospectively for the development of ...
McNeeley, S. Gene +3 more
openaire +5 more sources
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2 [PDF]
, 2017 Objective: An integrated analysis was undertaken to characterize the antitumor activity and safety profile of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with relapsed high-grade ovarian carcinoma (HGOC). Methods: Eligible
Bell-McGuinn, Katherine +24 more
core +1 more source
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas [PDF]
, 2013 <b>Objective</b> <i>ABCB1</i> encodes the multi-drug efflux pump P-glycoprotein (P-gp) and has been implicated in multi-drug resistance.
+50 more
core +1 more source
Enhanced Recovery Pathways in Gynecology and Gynecologic Oncology [PDF]
Obstetrical & Gynecological Survey, 2015 Enhanced recovery programs (ERPs) are considered standard of care across a variety of surgical disciplines, but ERPs have not been widely adopted in gynecology.
Emma L. Barber, Linda Van Le
openaire +2 more sources
Genome-wide methylome analysis using MethylCap-seq uncovers 4 hypermethylated markers with high sensitivity for both adeno- and squamous-cell cervical carcinoma [PDF]
, 2016 Background: Cytology-based screening methods for cervical adenocarcinoma (ADC) and to a lesser extent squamous-cell carcinoma (SCC) suffer from low sensitivity.
Boers, Aniek +9 more
core +2 more sources